Cryoport Inc., a leader in supply chain solutions for the life sciences, and VGXI Inc.,a contract developer and manufacturer specializing in nucleic acid biopharmaceuticals, have announced a strategic partnership to support the development of cell and gene therapies and mRNA-based treatments.
 
Through this new partnership, Cryoport Systems will provide biostorage and bioservices from its Houston, Texas, facility for plasmid DNA products manufactured at VGXI’s facilities in The Woodlands, Texas, and its new headquarters and manufacturing location in Conroe, Texas.
 
This collaboration combines VGXI’s proficiency in plasmid DNA production with Cryoport’s comprehensive, fully integrated supply chain solutions. These include shipping services, data solutions, and extensive support services, all designed to ensure a smooth final delivery to VGXI’s customers. Operations under this partnership are scheduled to begin in October 2024.
 
Jerrell Shelton, CEO of Cryoport, commented, “Being chosen by VGXI as a partner for biostorage and bioservices underscores our shared commitment to quality and innovation. VGXI has a proven track record of delivering high-quality plasmid DNA for commercial gene therapies and clinical trial testing of leading treatment candidates. Together, we will provide biopharmaceutical companies a comprehensive and integrated solution to support clinical programs that are developing lifesaving, next-generation therapeutic modalities, a key part of our mission.”
 
Young Park, CEO of VGXI, added, “We are thrilled to launch this partnership to support our client’s advanced therapy programs, including cell and gene therapies, mRNA-based treatments and DNA vaccines. Choosing Cryoport as our trusted and reliable partner further elevates our mission by ensuring safe, secure, and world-class storage and transport of these assets.”

Related News